Back to results

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

Objective

Cohort A Phase II: - The proportion of patients who are ctDNA(-) after 12 weeks of treatment. Cohort A Phase III: - Overall survival Cohort B: - Disease-free survival (DFS).

Protocol #

A032103

Trial Phase:

Phase II/III

Principal Investigator:

Melson, John

Cancer Type
  • Other Urinary
  • Urinary Bladder
Study Site
  • Stony Point
  • Virginia Commonwealth University

Histologically confirmed muscle-invasive urothelial carcinoma of the bladder
Age >/= 18 years
Patient must have had radical cystectomy and lymph node dissection >/= 3 weeks, but </= 12 weeks prior to pre-registration.
No gross cancer at the surgical margins
No evidence of residual cancer or metastasis after cystectomy

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Melanie Hamilton, RN
    Phone: +1 804-628-7130
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: